Suppr超能文献

使用缓释注射用阿立哌唑成功治疗双相I型障碍的抑郁症状

Using Extended-Release Injectable Aripiprazole for the Successful Treatment of Depressive Symptoms in Bipolar I Disorder.

作者信息

Kuo Joseph, Lin Shih-Ku

机构信息

Department of Psychiatry, Camillians Saint Mary's Hospital Luodong, Yilan, Taiwan.

Taipei City Hospital and Psychiatric Center, Taipei, Taiwan.

出版信息

Case Rep Psychiatry. 2020 Feb 21;2020:2615748. doi: 10.1155/2020/2615748. eCollection 2020.

Abstract

Extended-release injectable (ERI) aripiprazole is indicated for schizophrenia and maintenance monotherapy of bipolar I disorder. Clinical trials of aripiprazole failed to exhibit efficacy in the treatment of bipolar depression. It has been suggested that relatively high doses, rapid titration of dose, a high dropout rate, and a high placebo effect might be the reasons of its ineffectiveness. Here, we report a case of a 39-year-old woman with bipolar depression who was successfully treated with ERI aripiprazole.

摘要

长效注射用阿立哌唑适用于精神分裂症及双相I型障碍的维持单药治疗。阿立哌唑的临床试验未能显示出其在双相抑郁治疗中的疗效。有人认为,相对高的剂量、快速的剂量滴定、高脱落率和高安慰剂效应可能是其无效的原因。在此,我们报告一例39岁双相抑郁女性患者,其接受长效注射用阿立哌唑治疗取得成功。

相似文献

本文引用的文献

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验